What changed for Type 1 Diabetes
A plain English summary of what recently moved in the public data Voxsanity tracks for Type 1 Diabetes. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 315 to 320 (+5)
- Trials on record 3,389 to 3,413 (+24)
Newly subsidised on the PBS
1 medicine newly subsidised on the PBS for Type 1 Diabetes in July 2026:
- Insulin degludec
"Newly subsidised" means the medicine reached the PBS this month, not that a new pack size or brand of an existing listing was added. Verify current PBS status with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 280 trials tracked for Type 1 Diabetes that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03263494 · results posted 9 July 2026
According to the results reported on ClinicalTrials.gov, this trial involved 153 adults who were split into two groups: 74 people used a Continuous Glucose Monitor (CGM) — a small wearable sensor that tracks blood sugar levels automatically throughout the day — and 79 people used a standard Blood Glucose Monitor (BGM), which requires a finger-prick test. The trial was measuring changes in a blood test called HbA1c over 26 weeks. HbA1c is a measure of average blood sugar levels over roughly the past three months, expressed as a percentage. All 153 participants completed the study with no dropou...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05144802 · results posted 17 June 2026
According to the results reported on ClinicalTrials.gov, this trial involved 30 people in total — 15 in Group 1 and 15 in Group 2. All 30 participants completed the study with no drop-outs. The trial was measuring how accurately a continuous glucose monitor (CGM) — a small wearable device that tracks blood sugar levels — compared to blood sugar readings taken from a vein (considered the standard reference method). The main measurement used to assess this accuracy was something called the Mean Absolute Relative Difference, or MARD, which is essentially the average percentage gap between what th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06728059 · results posted 28 May 2026
According to the results reported on ClinicalTrials.gov, this trial involved 15 people in total — 8 in one group and 7 in the other. It was a crossover study, meaning both groups used two different versions of an automated insulin delivery system (called AIDANET, and AIDANET with an added feature called BPS-RL) at different points in time. The trial measured how well each system kept blood sugar levels within a target range (70–180 mg/dL), using a continuous glucose monitor (CGM) — a small device that tracks blood sugar automatically. Measurements were taken both during supervised overnight ho...
-
NCT05571293 · results posted 22 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 26 people across three groups (called cohorts): 12 in Cohort A, 13 in Cohort B, and 1 in Cohort C. The trial was looking at how colon cancer tumours responded to immunotherapy drugs — botensilimab and balstilimab — given before surgery, by examining the removed tissue afterwards. It was also measuring whether serious side effects occurred, whether treatment caused surgery to be delayed, and tracking a blood-based marker called circulating tumour DNA (ctDNA), which can indicate whether tiny amounts of cancer remain in...
-
NCT03895437 · results posted 20 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03895437) enrolled 78 people in total — 51 received an investigational treatment called TOL-3021, and 27 received a placebo (an inactive substitute used for comparison). The trial was measuring whether TOL-3021 had any effect on the body's remaining ability to produce insulin, in people living with type 1 diabetes. The main thing being tracked was a substance called C-peptide, which is a marker of the body's own insulin production, measured via a standardised meal test at 12, 16, and 24 weeks. It is worth noting that the t...
-
NCT04291703 · results posted 7 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04291703) enrolled a very small number of participants — just one person in the Antithymocyte Globulin (ATG) group and one person in the Placebo group, for a total of two participants. The trial was measuring how long it took for people at an early stage of type 1 diabetes (Stage 2) to progress to a more advanced stage (Stage 3), where blood sugar levels become noticeably abnormal and a formal diabetes diagnosis is made. Both participants completed the study. The reported data shows that the single participant who receive...
-
NCT05418699 · results posted 12 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 410 adults with Type 1 diabetes. All 410 participants were still involved at the 3-month mark, 406 remained at 6 months, 401 at 12 months, and 391 completed the full study, with 19 people not completing it. The trial was tracking two main things: HbA1c levels — a blood test that reflects average blood sugar control over roughly 2–3 months — and "time in range," meaning the proportion of time a person's blood sugar stayed within a target zone (between 70 and 180 mg/dL). The reported data shows that the primary outcome...
-
NCT05413239 · results posted 12 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 191 young people with type 1 diabetes — 95 in the intervention group and 96 in the control group. By the end of the 12-month study, 86 and 85 participants respectively had completed it. The trial was measuring how much time participants' blood sugar levels spent within a healthy target range (between 70 and 180 mg/dL), using a continuous glucose monitor (a small wearable sensor that tracks blood sugar throughout the day). It also tracked a blood test called HbA1c (a measure of average blood sugar over roughly three mo...
-
NCT05508061 · results posted 17 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 12 participants in total — 5 in one group and 7 in the other — and all 12 completed the study with no dropouts. It was a crossover trial, meaning each participant used both insulin types (Lyumjev and Humalog, which are both forms of insulin lispro) at different times, so the same people contributed data to both treatment periods. The main thing the trial set out to measure was how much time participants spent with blood glucose levels above 10 mmol/L (a level considered above the healthy target range). The reported d...
-
NCT05431686 · results posted 22 December 2025
According to the results reported on ClinicalTrials.gov, this trial looked at whether a type of group medical appointment — called a Shared Medical Appointment (SMA) — was a practical and acceptable way to support young people managing diabetes with a continuous glucose monitor (CGM, a small wearable device that tracks blood sugar levels throughout the day). Fourteen participants were enrolled in the single study arm, though only 4 completed the study and 10 did not complete it. The trial was measuring several things related to feasibility — that is, whether running this kind of program was re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03534193 · results posted 17 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03534193) involved 28 people who had recently been diagnosed with Type 1 diabetes. They were split into two groups of 14: one group received standard diabetes education only, and the other received standard diabetes education plus a tablet-based education program. The trial was measuring whether adding a tablet-based learning tool made a difference in diabetes knowledge, blood sugar control, and the number of low blood sugar episodes. By the end of the study, 13 people completed the standard education group and 11 complete...
-
NCT04118374 · results posted 28 October 2025
According to the results reported on ClinicalTrials.gov, this trial involved 12 adults in total, split into two groups of six. It was a crossover study, meaning every participant tried both diets — a standard carbohydrate diet and a low carbohydrate diet — each for one week, with a three-week break in between. The trial was measuring insulin sensitivity, which is how well the body responds to insulin to manage blood sugar levels. This was tested using a specialised procedure called a hyperinsulinemic-euglycemic clamp, which carefully controls blood sugar while measuring how much glucose (sugar...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05992350 · results posted 20 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 45 participants across two groups — 24 in the "Primary Analysis Arm" and 21 in the "Parent Arm." The study was measuring several things related to type 1 diabetes management, including how much moderate-to-vigorous physical activity participants did each day, how often they were hospitalised for a serious diabetes complication called diabetic ketoacidosis (a dangerous build-up of acids in the blood), how much time their blood sugar levels stayed within a healthy range, and whether machine learning (computer-based pred...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04955691 · results posted 16 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 19 people in total, split into two groups of 9 and 10. It used a "crossover" design, meaning everyone tried both diets — a low carbohydrate diet and a standard carbohydrate diet — one after the other, with a break (washout period) in between. The trial was measuring how blood sugar levels behaved during each diet, using a continuous glucose monitor worn over two weeks at a time. All 19 participants started and were analysed, though three did not complete the final phase. The reported data shows that the main thing be...
-
NCT04016415 · results posted 2 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04016415) enrolled 309 adults with diabetes — 154 assigned to a Mindfulness-Based Stress Reduction (MBSR) program and 155 assigned to a Stress Management Education (SME) program. The trial was measuring whether a mindfulness program, compared to a general stress education program, would change participants' blood sugar control (using a home HbA1c test — a measure of average blood sugar levels over roughly three months), their diabetes-related distress, and their general feelings of stress, at two months and six months afte...
-
NCT03406897 · results posted 17 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 27 people in total — 12 in a group receiving a combination of omega-3 and vitamin D, and 15 in a group receiving vitamin D only. The trial was looking at whether these supplements might affect the body's remaining ability to produce its own insulin in people with type 1 diabetes, measured using a special test called a Mixed Meal Tolerance Test (MMTT), which involves a meal-like drink and a blood test 90 minutes later to check a substance called C-peptide (a marker of the body's own insulin production). Not everyone fi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06017089 · results posted 15 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06017089) enrolled 32 adults who used an AI-guided, at-home "closed loop" insulin delivery system — a type of automated insulin pump that adjusts doses based on continuous glucose readings. Of the 32 who started, 28 completed the trial. The study compared participants' glucose readings during a baseline period (before the AI system was active) against their readings while using the AI-guided system. The reported data shows the following glucose measurements, captured by a continuous glucose monitor (a small sensor worn on...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03608163 · results posted 11 September 2025
According to the results reported on ClinicalTrials.gov, this trial involved just 4 participants in total, split into two groups of 2. It used a "crossover" design, meaning each person received both naloxone (a medication) and a placebo (an inactive substitute) at different times, with a washout period of roughly 6 months in between. The trial was measuring whether naloxone could affect the body's hormonal and physical responses during episodes of low blood sugar (hypoglycaemia) that were deliberately and safely induced in a controlled clinical setting. The reported data shows the following n...
-
NCT04385888 · results posted 26 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04385888) looked at whether reducing low-calorie sweetener consumption made a difference to blood sugar patterns and a few other body measurements in children and their parents. A total of 62 people started the initial run-in phase (31 children and 31 parents across both groups), and after that phase, 28 children and 28 parents were randomly placed into either a "low-calorie sweetener restriction" group or a "usual consumption" control group. By the end of the trial, 13 children and 13 parents completed each group. The re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06018844 · results posted 19 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 1 participant in a single group called the "Primary Arm." The study was designed to look at how a text message-based tool called the "NUDGE bot" might interact with young people, and to measure their levels of moderate to vigorous physical activity (that is, exercise intense enough to raise the heart rate noticeably). It also tracked a number of secondary measures, including how consistently participants wore a physical activity monitoring device (called an Actigraph), how often they completed daily physical activity...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03638141 · results posted 17 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 21 people who received a combination of two immunotherapy drugs — durvalumab and tremelimumab. Twenty of those participants completed the study, and one did not. The trial was measuring how the combination affected a type of liver cancer, looking mainly at how many patients' tumours shrank or disappeared, and also tracking how long participants lived without their disease getting worse, how long they survived overall, and what serious side effects occurred. The reported data shows that out of 21 participants, 11 had...
-
NCT05537233 · results posted 12 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 72 adults with type 1 diabetes — 36 in the semaglutide group and 36 in the control (placebo) group. The trial ran for 26 weeks and was measuring whether semaglutide, compared to placebo, could help participants reach a combined ("composite") goal: spending more than 70% of the day with blood sugar in a healthy range, spending less than 4% of the day with blood sugar too low, and losing at least 5% of their body weight — all tracked using a continuous glucose monitor (a small wearable device that reads blood sugar leve...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02213003 · results posted 12 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02213003) involved **3 people** who all received islet transplantation — a procedure where insulin-producing cells are transplanted into the body, in this case into a fold of tissue in the abdomen called the omentum. All 3 participants completed the study. The trial was measuring two main things: first, whether participants reached a certain blood sugar control level (a measure called HbA1c at or below 6.5%) without experiencing serious low blood sugar episodes; and second, whether participants had any complications relate...
-
NCT04404556 · results posted 15 July 2025
According to the results reported on ClinicalTrials.gov, this trial involved 162 young people with Type 1 diabetes, split into two groups: 97 in the "Diabetes Journey" group and 65 in the "Enhanced Standard of Care" group. The trial was measuring how much of a barrier diabetes management felt to participants — specifically around stress and burnout, and around the time and planning demands of managing diabetes day-to-day. Participants were followed across several stages: during the program, immediately after, and at two further follow-up points. The reported data shows that for the stress and...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05916131 · results posted 18 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 people across four groups: one group received Hypoglycemia Symptom Detection Training, one received an approach called Education Plus, one received both of those interventions combined, and one received usual care. The trial was primarily designed to test whether running the study was practical — specifically, whether the researchers could recruit enough people to reach a target of 20 participants completing the 12-week intervention period. It was not designed at this stage to test whether any particular treatment...
-
NCT03013491 · results posted 17 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03013491) tested an investigational drug called CX-072, either on its own or combined with other drugs (ipilimumab or vemurafenib), in people with advanced cancer. The trial was split into several parts testing different doses, and a total of 196 participants took part across all groups. The main thing the trial was set up to measure was how many participants at each dose level experienced what are called "dose-limiting toxicities" (DLTs) — that is, serious side effects considered severe enough to potentially limit how muc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04848480 · results posted 12 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 582 adults in total — 290 in a group taking a once-weekly insulin called insulin icodec (combined with a mealtime insulin called insulin aspart), and 292 in a group taking a once-daily insulin called insulin degludec (also combined with insulin aspart). The trial ran for 52 weeks in two back-to-back phases of 26 weeks each. It was primarily measuring changes in HbA1c — a blood test that reflects average blood sugar levels over roughly three months — between the start of the trial and week 26. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02218619 · results posted 5 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 people in total — 10 received a substance called TUDCA (taurourodeoxycholic acid, a bile acid compound) and 10 received a sugar pill (placebo). All 20 participants completed the trial. The main thing the trial was measuring was how well the insulin-producing cells in the pancreas were still working over time, using a marker called C-peptide (a substance released alongside insulin). Participants drank a mixed meal and had their C-peptide levels tracked; a higher score means more insulin-producing activity. The measu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06546657 · results posted 19 March 2025
According to the results reported on ClinicalTrials.gov, 89 people took part in this trial, which used a small wearable device called a continuous glucose monitor (CGM) to track blood sugar levels throughout the day. The trial was looking at what happens to blood sugar in the hours after eating breakfast. A total of 387 breakfast meals were tracked across the group, and 74 participants also completed questionnaires about their breakfast and how they felt after eating (71 finished that part of the study). The reported data shows that the average blood sugar level measured over the four hours a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05698875 · results posted 11 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05698875) enrolled 26 participants, all in a single group called "Breakfast Meals." The trial was measuring how blood sugar levels responded in the three hours after eating different breakfast meals. Participants were given four different meals to try: a high glycaemic load meal (HGL), a high glycaemic load meal with extra protein (HGLP), a medium glycaemic load meal (MGL), and a control meal. Blood sugar was tracked using a continuous glucose monitor (a small sensor worn on the body that records readings every five minute...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 280 reported results for Type 1 Diabetes
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research money is currently directed toward Type 1 Diabetes, and that investment is rising year on year. This signals that the global scientific community considers this condition a serious and active research priority. For patients, it means that laboratories and research teams are being supported to keep working, which tends to lay the...
See the full Type 1 Diabetes page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.